1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

HIK.L
Hikma Pharmaceuticals PLCGB flagLondon Stock Exchange
1,550.00
GBp
+2.00
- -
3.26BMarket Cap
Hikma Pharmaceuticals PLC
HIK.L
(London Stock Exchange)

Recent

price

1,550.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
3.8
4.73
5.65
6.93
7.52
7.24
8.37
8.07
8.59
9.12
9.92
11.05
11.24
13.02
14.13
15.18
Revenue per Share
0.51
0.41
0.51
1.08
1.4
1.27
0.67
-3.51
1.17
2.01
1.83
1.82
0.84
0.86
1.62
1.82
Basic EPS, GAAP
0.45
0.25
0.48
1.33
1.55
1.15
0.44
1.22
1.21
1.18
1.02
1.77
1.61
1.83
1.49
0.54
Free Cash Flow per Basic Share
0.12
0.13
0.14
0.2
0.28
0.32
0.33
0.33
0.35
0.4
0.46
0.52
0.56
0.62
0.79
0.84
Dividend per Share
2.31
2.53
2.88
3.79
4.93
0.18
5.52
5.92
6.72
8.32
8.19
9.66
9.52
9.95
10.85
11.77
Book Value per Share
2.5
2.01
2.11
2.98
3.1
3.74
2.97
3.1
3.86
5.35
5.39
6.82
4.57
5.02
5.26
6.51
Tangible Book Value per Share
192
194
196
197
198
199
233
240
241
242
236
231
224
221
221
221
Basic Weighted Avg Shares
731
918
1,109
1,365
1,489
1,440
1,950
1,936
2,070
2,207
2,341
2,553
2,517
2,875
3,127
3,349
Sales/Revenue/Turnover
20.43
12.93
15.06
25.79
28.68
28.4
15.85
16.68
17.92
20.34
23.92
23.38
19.15
21.22
19.57
18.9
Operating Margin (%)
38
47
59
75
72
73
146
1,241
121
99
91
144
193
198
168
238
Depreciation Expense
99
80
100
212
278
252
155
-843
282
486
431
421
188
190
359
402
Net Income, GAAP
17.73
11.1
18.94
27.52
22.1
20.13
24.76
- -
2.73
0.81
22.94
22.79
18.03
31.67
20.44
21.58
Effective Tax Rate (%)
13.52
8.73
9.02
15.53
18.67
17.5
7.95
-43.54
13.62
22.02
18.41
16.49
7.47
6.61
11.48
12
Profit Margin (%)
225
271
315
311
172
768
530
777
775
377
894
1,078
922
761
285
1,190
Working Capital
84
363
388
282
168
612
742
690
562
107
764
725
1,135
1,030
653
1,490
LT Debt
750
799
848
1,034
1,216
1,352
2,411
1,528
1,697
2,129
2,148
2,467
2,148
2,209
2,321
2,606
Total Equity
13.55
9.61
10.12
17.84
20.33
16.47
8.75
- -
16.64
18.49
15.74
15.66
12.75
13.46
15.51
13.93
Return on Invested Capital (%)
16.96
10.86
10.15
18.9
20.95
24.14
12.8
- -
14.23
21.51
17
15.59
7.16
6.97
11.68
11.75
Return on Capital (%)
23.27
17.14
18.95
32.32
32.25
49.8
23.47
-62.26
18.54
26.75
21.84
20.22
8.62
8.78
15.61
16.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
4.42%
12.28%
Free Cash Flow
9.86%
-2.35%
-63.83%
Net Income, GAAP
-71.05%
8.87%
11.98%
Sales/Revenue/Turnover
9.21%
7.55%
7.1%
Total Cash Common Dividend
11.44%
11.46%
5.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,875
2024
- -
- -
- -
- -
3,127
2025
- -
- -
- -
- -
3,349

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.86
2024
- -
- -
- -
- -
1.62
2025
- -
- -
- -
- -
1.82

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.62
2024
- -
- -
- -
- -
0.79
2025
- -
- -
- -
- -
0.84
Similar Companies
Filament Health Corp. (FH.NE)
YourWay Cannabis Brands Inc. (YOURF)
Deciphera Pharmaceuticals, Inc. (DCPH)
BC Craft Supply Co. Ltd. (CRFTF)
Yuyu Pharma, Inc. (000220.KS)
TerrAscend Corp. (TSNDF)
Business
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company that develops, manufactures and markets generic, branded generic and in-licensed products, including sterile injectables, oral solids, nasal sprays, respiratory products and biosimilars; it supplies over 800 medicines across therapeutic areas such as oncology, pain management, cardiovascular, diabetes, central nervous system, dermatology and respiratory to hospitals, clinics and retail markets. Hikma operates through three main segments--Injectables, which provides generic and specialty injectable medicines to North America, Europe and MENA; Branded, which offers branded generics and in-licensed patented products primarily in MENA; and Generics (Hikma Rx), which delivers oral, respiratory and specialty generics to the North American retail market--with manufacturing facilities in the US (Ohio, New Jersey), six MENA countries, Portugal, Italy, Germany and Jordan. The company, founded in 1978 and headquartered in London, UK, serves over 50 countries with a focus on North America, MENA and Europe. Recent developments include the acquisition of Xellia Pharmaceuticals' US finished dosage business in 2024 to strengthen injectables; agreement to acquire 17 Takeda brands licensed to Hikma; $1 billion US investment announced in June 2025 for manufacturing and R&D expansion in Ohio and New Jersey; $250 million financing deal with IFC in July 2025 to boost MENA operations; exclusive US partnership with Emergent BioSolutions for Kloxxado naloxone nasal spray in January 2025; exclusive MENA agreement with DGI Group for Claritag in November 2025; strengthened partnership with Celltrion for biosimilars in October 2025; launch of STARJEMZA ustekinumab biosimilar and liraglutide GLP-1 injection in the US in November 2025; centralisation of global R&D under a new structure in November 2025; and confirmation of 2025 revenue growth guidance of 4-6% with core operating profit of $730-750 million.

Company News

APIChatGPT

  • globenewswire.com

    Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million

  • proactiveinvestors.com

    Hikma falls to three-year low as CEO steps down with immediate effect